Whether adagrasib (Krazati) can treat pancreatic cancer and related clinical trial progress

Adagrasiib (Krazati) is an oral small molecule KRAS G12C inhibitor, mainly targeting patients with solid tumors carrying KRAS G12C mutations, including non-small cell lung cancer (NSCLC) and certain colorectal cancer patients. KRAS G12C mutations also exist in a certain proportion in pancreatic cancer, but compared with NSCLC and colorectal cancer, their incidence is relatively low. Therefore, in theory, adagrasib has the potential to be used in KRAS G12C-positive pancreatic cancer patients, but its clinical application is still in the exploratory stage.

Currently, clinical trials of adagrasib in pancreatic cancer are still in the early stages. Multiple international multi-center Phase I/II studies are evaluating its efficacy and safety in patients with KRAS G12C positive pancreatic cancer. Preliminary data show that some patients can achieve tumor shrinkage or disease control, but the overall objective response rate (ORR) is still lower than that of NSCLC patients. This may be related to the complex tumor microenvironment, poor angiogenesis and diverse drug resistance mechanisms of pancreatic cancer.

In terms of safety, the tolerability of adagrasib in patients with pancreatic cancer is generally controllable. Common adverse reactions include fatigue, nausea, diarrhea and mild abnormalities in hematological indicators. Clinical trials emphasize regular monitoring during treatment, including liver function, blood routine, and imaging assessments, in order to adjust the dose or deal with adverse events in a timely manner. For patients with other systemic diseases or who are undergoing chemotherapy, doctors will comprehensively evaluate the risks and benefits and formulate individualized treatment plans.

Generally speaking, the application of adagrasib in pancreatic cancer is still in the exploratory stage, and its potential value is mainly focused on the precise treatment of KRAS G12C positive patients. With the continuous accumulation of clinical trial data and the optimization of drug combination regimens, new treatment options may be provided for some patients with pancreatic cancer in the future. However, due to the highly aggressive and complex nature of pancreatic cancer, the drug's long-term efficacy, resistance mechanism and optimal usage strategy still need to be further verified. Patients should fully consult a professional doctor before use and make individualized decisions based on genetic testing results.

Reference link:https://www.drugs.com